Merck & Co., Inc. Reports Q3 2026 Financial Results

Merck reported a non-GAAP loss of $0.13 per share for Q3 2026, narrower than analysts’ expected $0.26 loss. Results included a $2.31-per-share charge related to its acquisition of Terns Pharmaceuticals. The company raised its 2026 revenue outlook to $66.3 billion–$67.3 billion but lowered adjusted EPS guidance to $2.66–$2.76. Keytruda and Keytruda QLEX generated combined revenue of $8.37 billion, up 5.2% year over year.